Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04984811
Title NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NeoImmuneTech

lung non-small cell carcinoma


Atezolizumab + NT-I7

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST